Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease  by Wood, William A. et al.
Figure 1. Six-month NRM is lower among steroid boost recipients compared
to ATG
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in this modern era.
Methods: We retrospectively analyzed day 28 response
rates and clinical outcomes of 113 HCT patients (median
age 39 years, range 1-75) who received second-line
therapy for SR-aGVHD from 1998-2012 at the University of
Minnesota.
Results: Patients received grafts from 43 related (38
matched, 5 mismatched), 31 unrelated (23 HLA 6-8/8, 8
HLA 25/8) and 39 cord blood donors (23 HLA 6-8/8, 16 HLA
25/8); 76 patients (67.3%) received myeloablative regi-
mens. Second-line therapy consisted of ATG (44.2%), MMF
(24.8%), steroid boost (22.1%) or other (8.8%). Patients
receiving ATG had higher-risk GVHD Risk Scores (Mac-
Millan et al, Br J Haem, 2012) at second-line initiation
compared with patients receiving MMF or steroids. At day
28, overall response (complete response [CR]/partial
response [PR]) was observed in 32 patients (28%). All
therapies had similar responses. In multivariate analysis,
factors associated with day 28 CR/PR included GVHD Risk
Score and days from onset of aGVHD to second-line
therapy (Table); Six-month non-relapse mortality (NRM)
was lower among patients receiving steroid boosts (24%
[7-41%, 95% CI]) vs. ATG (64% [48-90%, 95% CI]) with no
differences vs. MMF or other therapies (P¼0.01, Figure 1).Figure 2. Six-month OS is increased among day 28 second-line
responders.In multivariate analysis, use of steroids vs. ATG was
associated with reduced 6-month NRM (Table). Overall
survival (OS) at 6 months was increased among day 28
responders (68% [48-81, 95% CI]) vs. non-responders (NR)
(45% [33-57, 95% CI]) (P¼0.03, Figure 2). Donor and cell
source, conditioning regimen and age did not impact
response, NRM or OS.
Conclusions: Effective therapy for SR-aGHVD remains
inadequate. Day 28 CR/PR was similar among second-line
therapies. ATG recipients experienced higher rates of
NRM but also exhibited higher-risk GVHD by Risk Score.
Identiﬁcation of high-risk GVHD at initial onset using the
GVHD Risk Score may identify patients likely to fail
upfront steroids in need of additional or alternative
agents.513
Survival without Progressive Impairment As a Novel
Endpoint in Chronic Graft-Versus-Host Disease
William A. Wood 1, Stephanie J. Lee 2, Xiaoyu Chai 2,
Mary E.D. Flowers 2, Corey S. Cutler 3, Yoshihiro Inamoto 2,
Aleksandr Lazaryan 4, Joseph Pidala 5, Jeanne Palmer 6,
Paul J. Martin 2. 1 Division of Hematology/Oncology, University
of North Carolina-Chapel Hill, Chapel Hill, NC; 2 Clinical
Research Division, Fred Hutchinson Cancer Research Center,
Seattle, WA; 3Hematologic Malignancies, Dana-Farber Cancer
Institute, Harvard Medical School, Boston, MA; 4 University of
Minnesota Medical Center, Minneapolis, MN; 5 Blood and
Marrow Transplantation, H. Lee Mofﬁtt Cancer Center and
Research Institute, Tampa, FL; 6 Hematology Oncology/Blood
and Marrow Transplant, Mayo Clinic Arizona, Phoenix, AZ
Background: A primary goal in the management of chronic
graft-versus-host disease (cGVHD) is to prevent the pro-
gression of organ-speciﬁc and global functional impairment
due to the natural history of cGVHD or its treatment. We
tested a deﬁnition of progressive impairment in a multi-
center cohort.
Methods: Of the measures recommended by the 2005 NIH
Consensus Conference, changes in 21 items having face val-
idity for “impairment” were selected from these categories:
clinician-reported organ involvement; FEV1; and patient-
reported performance status and physical function.
Results: 575 patients were evaluated, and 237 (41%) met
criteria for progressive impairment during a median of 39.9
(range 3.8 to 69.2) months of follow-up. 125 (53%) had pro-
gressive impairment on the basis of clinically assessed mea-
sures, 61 (26%) on the basis of patient-reported performance
status or physical function, and 51 (22%) on the basis of more
than one category. The top 5 items indicating progressive
impairment were: decline in FEV1 by 10% (81/237), decrease
in the Human Activity Proﬁle Adjusted Activity Score (HAP
AAS) score by 0.5 standard deviation (76/237), increase in
the global measure of skin sclerotic changes (70/237), increase
in the fascia score (57/237), and increase in the global skin
score (51/237). Rates of survival without progressive impair-
ment or relapse were 72% at 6 months, 52% at 12 months, and
35% at 24 months. Cumulative incidences of progressive
impairmentwere 20% at 6months, 33% at 12months, and 43%
at 24 months. Patients with progressive impairment had sig-
niﬁcant worsening in clinician and patient-assessed cGVHD
severity, symptoms and quality of life as compared to those
without progressive impairment (Table).
Conclusion: Treatments that prevent unacceptable clinical
deterioration in patients with chronic GVHD could be iden-
tiﬁed by using survival without progressive impairment as
an endpoint in clinical trials.
Variable Change from enrollment to visit with progressive
impairment (N¼237)
Change from enrollment to last visit without
impairment (N¼130)
p-value
N Median Mean Min Max N Median Mean Min Max
MD 0-3* 233 0 -0.15 -3 2 128 0 -0.59 -3 1 <0.001
MD 0-10** 232 -1 -0.64 -8 6 128 -2 -1.98 -8 2 <0.001
PT 0-3* 179 0 -0.01 -2 2 59 -1 -0.58 -2 1 <0.001
PT 0-10** 176 0 -0.37 -7 6 63 -2 -1.62 -6 3 <0.001
FACT-BMT 180 -0.92 0 -44.67 54.67 60 13 15 -24.33 45.94 <0.001
Lee symptom summary 190 -0.27 -0.46 -45.22 33.57 63 -6.05 -7.59 -38.81 10.85 <0.001
FACT-BMT ¼ functional assessment of cancer therapy, bone marrow transplant
*Clinician (MD) or Patient (PT)-rated overall chronic GVHD severity on a 0-3 scale (none, mild, moderate, severe)
**MD or PT-rated overall chronic GVHD severity on a 0-10 scale
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Purpose: Graft-versus-host-disease (GVHD) affects more
than 50% of transplanted patients and is a major obstacle to
successful allogeneic stem cell transplantation (alloSCT).
Cannabidiol (CBD), a non-psychotropic ingredient of
Cannabis has been shown to exhibit potent anti-inﬂamma-
tory properties in animal models of various autoimmune
diseases like multiple sclerosis, rheumatoid arthritis, in-
ﬂammatory bowel disease and diabetes mellitus. We hy-
pothesized that the addition of CBD to standard GVHD
prophylaxis may decrease GVHD incidence and severity.Figure 1Patients and Methods:We conducted a prospective phase I/
II study (NCT01385124). Patients were given oral CBD 300
mg/day from day -7 through day +30 plus standard
GVHD immunoprophylaxis consisting of cyclosporine and
methotrexate.
Results: Forty-eight consecutive adult patients undergoing
alloSCT were enrolled. Thirty-eight patients (79%) had acute
leukemia or MDS and 13 patients (27%) had progressive
disease. Thirty-ﬁve patients (73%) were given a myeloa-
blative conditioning. The donor was either an HLA identical
sibling (n¼28), a 10/10 matched unrelated donor (n¼16) or a
1-antigen mismatched unrelated donor (n¼4). Median
follow-up was 16 (range, 7-23) months. There were no grade
3-4 toxicities attributed to CBD. The cumulative incidences of
grade 2-4 and grade 3-4 acute GVHD by day 100 were 12%
and 5%, respectively. None of the patients developed acute
GVHD while consuming CBD. Compared to 101 historical
control subjects given standard GVHD prophylaxis, the haz-
ard ratio of developing grade 2-4 acute GVHD among sub-
jects treated with CBD plus standard GVHD prophylaxis was
0.3 (95% CI: 0.2-0.6; p¼0.0002). The cumulative incidence
of moderate-to-severe chronic GVHD at 1 year was 20%.
Relapse rate, non-relapse mortality and overall survival at 1
year were 41%, 11.1% and 68%, respectively.
Conclusions: The combination of CBD with standard GVHD
prophylaxis is a safe and promising strategy to reduce the.
